title: Visible persistence decay rates for schizophrenics and substance abusers.
abstract: Information-processing deficits are consistently reported for schizophrenics. The findings from the majority of psychophysical tasks indicate that the deficit is specific to schizophrenics and thus may represent a marker for schizophrenia. The present study evaluated for specificity of impairment by including controls using methadone. A two-pulsed forced choice information-processing task that required the detection of a line or a blank-field during an interstimulus interval (ISI) indexed efficiency of processing (i.e., visible persistence). There were 19 schizophrenic, 9 schizoaffective, 8 depressed, 12 on methadone, and 12 normal subjects. The visual stimuli were low and high spatial frequency gratings. Either a line of equivalent width to those of the gratings or a blank field was presented during the ISI. The gratings were presented for 150 msec prior to and following an ISI of 30, 60, 90, 120, 150, and 350 msec. The results support previous findings for impaired processing during a 90-150 msec interval for schizophrenics. Also, the methadone-using controls were not significantly different from schizophrenics. Normal and depressed controls' profiles did not differ from each other, however, they were significantly different from the other groups. The results support an early information-processing deficit in schizophrenic individuals and may implicate dysregulation of dopaminergic neuromodulation.
authors.affiliation: Department of Psychiatry, Tulane University Medical Center, New Orleans, LA 70112.
authors.forename: B D
authors.initials: BD
authors.lastname: Schwartz
authors.forename: W J
authors.initials: WJ
authors.lastname: Evans
authors.forename: J M
authors.initials: JM
authors.lastname: Pena
authors.forename: D K
authors.initials: DK
authors.lastname: Winstead
mesh_terms: D000328:Adult; D001288:Attention / Q000187:drug effects / Q000502:physiology; D003866:Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology; D004298:Dopamine / Q000502:physiology; D005260:Female; D005366:Figural Aftereffect / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D011939:Mental Recall / Q000502:physiology; D009483:Neuropsychological Tests; D009293:Opioid-Related Disorders / Q000503:physiopathology / Q000523:psychology* / Q000534:rehabilitation; D010364:Pattern Recognition, Visual / Q000187:drug effects / Q000502:physiology; D011618:Psychotic Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology; D012016:Reference Values; D012559:Schizophrenia / Q000175:diagnosis* / Q000503:physiopathology / Q000534:rehabilitation; D012565:Schizophrenic Psychology
chemical_list: D004298:Dopamine